Cocaine, dopamine and the endogenous opioid system

Journal of Addictive Diseases

Volumn 15, Issue 4, 1996, Pages 73-96

  Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE; DYNORPHIN; ENDORPHIN; KAPPA OPIATE RECEPTOR; NORADRENALIN; OPIATE RECEPTOR; SEROTONIN;

ARTICLE; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPIATE ADDICTION; PROSPECTIVE STUDY; RISK; SEROTONIN UPTAKE; UNITED STATES;

ANIMALS; BRAIN; COCAINE; DOPAMINE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMANS; METHADONE; NARCOTICS; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS;

EID: 0029855573     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v15n04_05     Document Type: Article

References (84)

1. Kreek MJ. Multiple drug abuse patterns and medical consequences. In: Meitzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press 1987:1597-1604.
2. Kreek MJ. Pharmacologic modalities of therapy: methadone maintenance and the use of narcotic antagonists. In: Stimmel B, ed. Heroin dependency: medical, economic and social aspects. New York: Stratton Intercontinental Medical Book Corp. 1975:232-290.
3. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O’Brien CP and Jaffe JH, eds. Addictive states New York: Raven Press, Ltd. 1992:205-230.
4. Novick DM, Trigg HL, Des Jarlais DC et al. Cocaine injection and ethnicity in parenteral drug users during the early years of the human immunodeficiency virus (HIV) epidemic in New York City. J Med Virol, 1989;:29:181-185.
5. Borg L, Broe DM, Ho A et al. Cocaine abuse is decreased with effective methadone maintenance treatment at an urban Department of Veterans Affairs (DVA) Program. In: Harris LS, ed. NIDA Research Monograph Series, Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIH Publication No. 95-3883, 1995:153:17.
6. Kreek MJ. Methadone maintenance treatment for harm reduction approach to heroin addiction. In: Loimer N, Schmid R, Springer A, eds. Drug addiction and AIDS. New York: Springer Verlag 1991:153-177.
7. Des Jarlais DC, Marmor M, Cohen H et al. Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. Morbidity and Mortality Weekly Report 1984:33:377-379.
8. Novick D, Kreek MJ, Des Jarlais D et al. Antibody to LAV, the putative agent of AIDS, in parenteral drug abusers and methadone-maintained patients: abstract of clinical research findings: therapeutic, historical, and ethical aspects. In: Harris LS, ed. NIDA Research Monograph Series, Problems of Drug Dependence, 1985; Proceedings of the 47th Annual Scientific Meeting of The Committee on Problems of Drug Dependence. Rockville MD:DHHS Publication No. (ADM)86-1448, 1986:67:318-320.
9. Novick DM, Farci P, Karayiannis P, Gelb AM, Stenger RJ, Kreek MJ, Thomas HC. Hepatitis D virus antibody in HBsAg-positive and HBsAg-negative substance abusers with chronic liver disease. J Med Virol 1985:15:351-356.
10. Novick DM, Khan I, Kreek, MJ. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. United Nations Bulletin on Narcotics. 1986:38:15-25.
11. Blix O. AIDS and IV heroin addicts: The preventative effect of methadone maintenance in Sweden. Proceedings of the 4th International Conference on AIDS, Stockholm, 1988:SR52.
12. Novick DM, Farci P, Croxson ST et al. Hepatitis delta virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive. J Infect Dis. 1988:158:795-803.
13. Novick DM, Des Jarlais DC, Kreek MJ et al. The specificity of antibody tests for human immunodeficiency virus in alcohol and parenteral drug abusers with chronic liver disease. Ale Clin Exp Res. 1988:12:687-690.
14. Des Jarlais DC, Friedman SR, Novick DM et al. HIV-1 Infection among intravenous drug users in Manhattan, New York City 1977 to 1987. JAMA. 1989:261:1008-1012.
15. Kreek MJ. HIV-1 infection and parenteral drug abuse: ethical issues in diagnosis, treatment, research and the maintenance of confidentiality. In: Allebeck P, Jansson B, eds. Proceedings of the Third International Congress on Ethics in Medicine-Nobel Conference Series. New York: Raven Press, 1990:181-187.
16. Kreek MJ. Immune function in heroin addicts and former heroin addicts in treatment: pre/post AIDS epidemic. In: Pham PTK and Rice K, eds. Current chemical and pharmacological advances on drugs of abuse which alter immune function and their impact upon HIV-1 infection. Rockville, MD: NIDA Research Monograph Series, 1990:96:192-219.
17. Brown LS, Kreek MJ, Trepo C et al. Human immunodeficiency virus and viral hepatitis seroepidemiology in New York City intravenous drug abusers (IVDAs). In: Harris LS, ed. Problems of Drug Dependence, 1989; Proceedings of the 51st Annual Scientific Meeting of the Committee on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series DHHS Publication No. (ADM) 90-1663, 1990:95:443-444.
18. Kreek MJ, Des Jarlais DC, Trepo CL et al. Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. J Infect Dis. 1990; 162:538-541.
19. Kreek MJ. Pharmacological treatment of addiction: Normalization of physiology and AIDS risk reduction. In: Tagliamonte A and Maremmani I, eds. Drug Addiction and Related Clinical Problems. Wien, Germany: Springer-Verlag, 1995:165-173.
20. Borg L and Kreek MJ. Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-positive and AIDS patients. Current Opinion in Psychiatry 1995; 8:199-202.
21. Kreek MJ. Biological correlates of methadone maintenance pharmacotherapy. In: Christoforov B, ed. Ann. Med. Interne: Intéréts et Limites des Traitements de Substitution dans la Prise en Charge des Toxicomanes. Paris: Masson, 1994:145:9-14.
22. Kreek MJ. Medical safety, side effects and toxicity of methadone. Proceedings of the Fourth National Conference on Methadone Treatment. NAPANNIMH, 1972:171-174.
23. Kreek MJ. Medical safety and side effects of methadone in tolerant indi-viduals. J Amer Med Assn. 1973: 223:665-668.
24. Kreek MJ. Physiological implications of methadone treatment. In: Methadone Treatment Manual. Washington, D.C.: U.S. Dept, of Justice (USGPO) #2700-00227, 1973:85-91.
25. Kreek MJ. Epilogue: Medical maintenance treatment for heroin addiction, from a retrospective and prospective viewpoint. In: State Methadone Maintenance Treatment Guidelines. Office for Treatment Improvement, Division for State Assistance, 1992:255-272.
26. Kreek MJ. The addict as a patient. In: Lowinson JH, Ruiz P, Millman RB and Langrod JG, eds. Substance Abuse: A Comprehensive Textbook. Baltimore, Maryland: Williams & Wilkins, 1992:997-1009.
27. Kreek MJ. Pharmacology and medical aspects of methadone treatment. In: Rettig RA and Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, D.C.: National Academy of Sciences, National Academy Press, 1995:37-60.
28. Ingoglia NA and Dole VP. Localization of dand 1-methadone after intraventricular injection into rat brain. Journal of Pharmacology and Experimental Therapeutics. 1970: 175:84-87.
29. Dole VP, Biochemistry of addiction. Annual Review of Biochemistry. 1970:39:821-240.
30. Goldstein A, Lowney LT, Pal BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 1971:68:1742-1747.
31. Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science. 1973:179:1011-1014.
32. Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic [3H]Etorphine to rat-brain homogenate. Proceedings of the National Academy of Sciences, 1973:70:1947-1949.
33. Terenius L. Stereospecific interaction between narcotic analgesics and a synaptic plasma membrane fraction of rat cerebral cortex. Acta Pharmacologica ET Toxicologica. 1973:32:317-320.
34. Evans CJ, Keith DE Jr., Morrison H, Magendzo, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science. 1992:258:1952-1955.
35. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delto-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proceedings of the National Academy of Science. 1992:89:12, 048U2, 052.
36. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional. expression of a mu opioid receptor from rat brain. Molecular Pharmacology. 1993:44:8-12.
37. Wang JB, Imai Y, Eppler CM, Gregor P, Spviak C, Uhl GR. Mu-opiate re-ceptor: cDNA cloning and expression. Proceedings of the National Academy of Sciences. 1993:90:10, 230-10, 234.
38. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochemical Journal. 1993:295:625-628.
39. Meunier JC, Mollereau C, Toll L et al. Isolation and structure of the endog-enous agonist of opioid receptor-like ORLj receptor. Nature. 1995:377:532-535.
40. Reinscheid RK, Nothacker HP, Bourson A et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 1995:270: 792-794.
41. Spangler R, Ho A, Zhou Y et al. Regulation of kappa opioid receptor mRNA in the rat brain by “binge” pattern cocaine administration and correlation with preprodynorphin mRNA. Mol Brain Res. 1996:38:71-76.
42. Branch AD, Unterwald EM, Lee SE, Kreek MJ. Quantitation of preproen-kephalin mRNA levels in brain regions from male Fischer rats following chronic cocaine treatment using a recently developed solution hybridization procedure. Mol Brain Res. 1992: 14:231-238.
43. Unterwald EM, Rubenfeld JM, Imai Y et al. Chronic opioid antagonist ad-ministration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Mol Brain Res. 1995:33:351-355.
44. Spangler R, Zhou Y, Unterwald EM, Kreek MJ. Opioid peptide and receptor mRNA levels in the rat brain determined by TCA precipitation of mRNA: cRNA hybrids. In: Harris LS, ed. Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 95-3883. 1995:153:484.
45. Spangler R, Unterwald EM, Branch A et al. Chronic cocaine administration increases prodynorphin mRNA levels in the caudate putamen of rats. In: Harris LS, ed. Problems of Drug Dependence, 1992; Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence Rockville, MD: NIDA Research Monograph Series, DHHS Publication No. (ADM) 93-3505. 1993:132:142.
46. Spangler R, Unterwald EM, Kreek MJ. ‘Binge’ cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Mol Brain Res. 1993: 19:323-327.
47. Zhou Y, Spangler R, Ho A et al. Corticotropin-releasing hormone (CRH) mRNA diurnal rhythms in rat hypothalamus and frontal cortex and inhibition by dexamethasone. In: Harris LS, ed. Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 95-3883. 1995:153:114.
48. Zhou Y, Spangler R, LaForge KS, Kreek MJ. Attenuation of the hypothalamic-pituitary-adrenal response to chronic “binge” pattem cocaine administration corresponds to decreased CRH mRNA in rat hypothalamus. Regulatory Peptides: Proceedings of the 25th International Narcotics Research Conference. 1994:54:345-346.
49. Zhou Y, Spangler R, LaForge KS et al. Regulation of POMC gene expression in rat pituitary, hypothalamus and amygdala by chronic administration of CRH, dex, and methadone. In: Harris LS, ed. Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series. Publication No. 96-4116. 1996:162:183.
50. Zhou Y, Spangler R, LaForge KS et al. Modulation of CRF-R1 mRNA in rat anterior pituitary by dexamethasone: correlation with POMC mRNA. Peptides. 1996:17:435-441.
51. Kreek MJ. Effects of opiates, opioid antagonists, and cocaine on the en-dogenous opioid system: clinical and laboratory studies. In: Harris LS, ed. Problems of Drug Dependence, 1991: Proceedings of the 53rd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Rockville, MD: NIDA Monograph, DHHS Publication No.(ADM) 92-1888. 1992:119:44-48.
52. Moldow RL, Fischman AJ. Cocaine induced secretion of ACTH, beta-endorphin and corticosterone. Peptides. 1987:8:819-822.
53. Samyai Z, Biro E, Penke B, Telegdy G. The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. Brain Res. 1992:589:154-156.
54. Mello NK, Samyai Z, Mendelson JH et al. Acute effects of cocaine on anterior pituitary hormones in male and female rhesus monkeys. Journal of Pharmacological Experimental Therapy. 1993:266:804-811.
55. Rivier C, Lee S. Stimulatory effect of cocaine on ACTH secretion: role of the hypothalamus. Mol. and Cell. Neurosciences. 1994:5:189-195.
56. Mello NK, Samyai Z, Mendelson JH et al. Acute effects of cocaine on anterior pituitary hormones in ovariectomized female rhesus monkeys. Journal of Pharmacological Experimental Therapy. 1995:272:1059-1066.
57. Kreek MJ. Medical complications in methadone patients. Ann NY Acad Sei. 1978:311:110-134.
58. Kreek MJ, Wardlaw SL, Friedman J et al. Effects of chronic exogenous opioid administration on levels of one endogenous opioid (beta-endorphin) in man. In: Simon E and Takagi H, eds. Advances in Endogenous and Exogenous Opioids. Tokyo, Japan: Kodansha Ltd. Publishers. 1981:364-366.
59. Kreek MJ, Hartman N. Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids and toxicity. Ann NY Acad Sei. 1982:398:151-172.
60. Kreek MJ, Wardlaw SL, Hartman N et al. Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sciences, Sup. 1.1983:33:409-411.
61. Kreek MJ, Raghunath J, Plevy S et al. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides. 1984:5:277-278.
62. Kosten TR, Kreek MJ, Swift C et al. Beta-endorphin levels in CSF during methadone maintenance. Life Sciences. 1987:41:1071-1076.
63. Kennedy JA, Hartman N, Sbriglio R et al. Metyrapone-induced withdrawal symptoms. Brit J Addict. 1990: 85:1133-1140.
64. Kosten TR, Morgan C, Kreek MJ. Beta-endorphin levels during heroin, methadone, buprenorphine and naloxone challenges: Preliminary findings. Biolog Psych. 1992:32:523-528.
65. Kreek MJ. Tolerance and dependence: Implications for the pharmacological treatment of addiction. In: Harris LS, ed. Problems of Drug Dependence, 1986; Proceedings of the 48th Annual Scientific Meeting of The Committee on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, DHHS Publication No.(ADM) 87-1508. 1987:76:53-61.
66. Cushman P, Kreek MJ. Some endocrinologic observations in narcotic addicts. In: Zimmerman E and George R, eds. Narcotic and the Hypothalamus. New York: Raven Press. 1974:161-173.
67. Tabasco-Minguillan J, Novick DM, Kreek MJ. Liver function tests in nonparenteral cocaine users. In: Harris LS, ed. Problems of Drug Dependence, 1990; Proceedings of the 52nd Annual Scientific Meeting of the Committee on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, DHHS Publication No. (ADM) 91-1753. 1991:105:372.
68. Kreek MJ. Multiple drug abuse patterns: Recent trends and associated medical consequences. Advances in Substance Abuse: Behavioral and Biological Research. London, England: Jessica Kingsley Publishers Ltd. 1991:4:91-111.
69. Unterwald EM, Horne-King J, Kreek MJ. Chronic cocaine alters brain mu opioid receptors. Brain Res. 1992:584:314-318.
70. Unterwald EM, Cox BM, Kreek MJ et al. Chronic repeated cocaine admin-istration alters basal and opioid-regulated adenylyl cyclase activity. Synapse. 1993:15:33-38.
71. Maisonneuve IM, Kreek MJ. Acute tolerance to the dopamine response in-duced by a binge pattern of cocaine administration in male rats: An in vivo microdialysis study. J Pharmacol and Exp Therapeutics. 1994:268(2):916-921.
72. Unterwald EM, Rubenfeld JM, Kreek MJ. Repeated cocaine administration upregulates k and p, but not 6, opioid receptors. NeuroReport. 1994: 5:1613-1616.
73. Unterwald EM, Ho A, Rubenfeld JM, Kreek MJ. Time course of the devel-opment of behavioral sensitization and dopamine receptor upregulation during binge cocaine administration. J Pharmacol and Exp Therapeutics. 1994:270(3): 1387-1397.
74. Maisonneuve IM, Ho A, Kreek MJ. Chronic administration of a cocaine “binge” alters basal extracellular levels in male rats: An in vivo microdialysis study. J Pharmacol and Exp Therapeutics. 1995:272:652-657.
75. Maggos CE, Spangler R, Zhou Y, Kreek MJ. Dopamine transporter mRNA levels in the rat substantia nigra and ventral tegmental area immediately following and at two days and ten days after ‘binge’ cocaine administration. In: Harris LS, ed. Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 95-3883. 1995:153:508.
76. Maggos CE, Spangler R, Zhou Y et al. Quantification of dopamine transporter mRNA in rat brain and modulations by dopamine receptor antagonists and cocaine. In: Harris LS, ed. NIDA Research Monograph Series, Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. Publication No. 96-4116. 1996:162:218.
77. Claye LH, Unterwald EM, Ho A, Kreek MJ. Both dynorphin Ai_i7 and [des-tyr1] dynorphin A2-17 inhibit adenylyl cyclase activity in rat caudate putamen. J Pharmacol and Exp Therapeutics. 1996 (in press).
78. Kreek MJ, Ho A, Borg L. Dynorphin AJ.B administration causes elevation of serum levels of prolactin in human subjects. In: Harris LS, ed. Problems of Drug Dependence, 1993; proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 94-3749.1 141:108, 1994.
79. Chou JZ, Pinto S, Kreek MJ, Chait BT. Study of opioid peptides by laser desorption mass spectrometry. In: Harris LS, ed. Problems of Drug Dependence, 1992; Proceedings of the 54th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, DHHS Publication No. (ADM) 93-3505. 1993:132:380.
80. Chou JZ, Maisonneuve IM, Chait BT, Kreek MJ. Study of dynorphin A(l-17) in vivo processing in rat brain by microdialysis and matrix-assisted laser desorption mass spectrometry. In: Harris LS, ed. Problems of Drug Dependence, 1993; Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 94-3749. 1994:141:240.
81. Chou JZ, Kreek MJ, Chait BT. Matrix-assisted laser desorption mass spec-trometry of biotransformation products of dynorphin A in vitro. J Am Soc Mass Spectrom. 1994:5:10-16.
82. Chou JZ, Chait BT, Kreek MJ. Study of dynorphin A peptides in vitro pro-cessing in human blood by matrix-assisted laser desorption mass spectrometry. In: Harris LS, ed. Problems of Drug Dependence, 1994; Proceedings of the 56th Annual Scientific Meeting of the College on Problems of Drug Dependence. Rockville, MD: NIDA Research Monograph Series, NIH Publication No. 953883. 1995:153:252.
83. Butelman ER, Yu J, Chou JZ et al. Dynorphin A (1-13): Biotransformation in human and rhesus monkey blood and antinociception. In: Harris LS, ed. Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. NIH Publication No. 96-41.16. 1996:162:225.
84. Yu J, Butelman ER, Woods JH et al. Studies of in vitro processing of dynorphin A (1-17) in human blood and in rhesus monkey blood. In: Harris LS, ed. Problems of Drug Dependence, 1995; Proceedings of the 57th Annual Scientific Meeting of the College on Problems of Drug Dependence. NIH Publication No. 96-4116. 1996:162:131.